Botulinum A toxin for treatment of aberrant facial nerve regeneration

Plast Reconstr Surg. 1993 May;91(6):1042-5. doi: 10.1097/00006534-199305000-00011.


Twelve patients with involuntary synkinetic eyelid closure were given 40 injections of botulinum A toxin. Temporary improvement in involuntary eyelid closure was observed in all 12 patients. Eleven of the 12 patients desired repeated injections. Dose requirements for this indication were compared with doses used in 697 injections in 112 patients with essential blepharospasm and Meige syndrome. Additionally, dose comparisons were made with 269 injections in 71 patients with hemifacial spasm. Dose requirements needed to treat aberrant regeneration of the facial nerve were substantially less than needed to treat blepharospasm and Meige syndrome. The dose requirement was similar to that in hemifacial spasm treatment. The reason for the differences probably relates to existing muscular denervation associated with hemifacial spasm and aberrant facial nerve regeneration.

MeSH terms

  • Blepharospasm / drug therapy*
  • Blepharospasm / etiology
  • Botulinum Toxins / adverse effects
  • Botulinum Toxins / therapeutic use*
  • Dose-Response Relationship, Drug
  • Facial Nerve / physiopathology*
  • Humans
  • Male
  • Middle Aged
  • Nerve Regeneration


  • Botulinum Toxins